This solution is used as a source of water, electrolytes, and calories, or as an alkalinizing agent to help restore fluid and acid–base balance in the bod

Each 100 ml of the solution contains 5 g of Dextrose, 600 mg sodium chloride, 310 mg sodium lactate, 30 mg potassium chloride, and 20 mg calcium chloride.

This is a sterile, non-pyrogenic solution used for fluid and electrolyte replacement, as well as providing calories. It is supplied in a single-dose container for intravenous administration.

As directed by a physician. Dosage is dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations. The dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low weight infants, because of the increased risk of hyperglycemia/ hypoglycemia. Additives may be incompatible. Administration Procedure: Check infusion set and infusion solution prior to use Pull moderately to tear off the protective cover of the Eurohead Hold lightly the Eurohead but not the bag Open the flow regulator fully and hold the giving set on the top white area, but not the membrane venting region Insert the spike of the administration set to the Eurohead and fit the connector of the administration set firmly to the needle Gradually allow the fluid to flow down to the needle tip and close Remove the protective cover of the needle Locate the veinpuncture site and clean the site with an antiseptic solution, and then insert the needle Securely tape the puncture site Securely tape the wings and tubing Start infusion while adjusting drip speed.

There are no known or well-documented drug interactions associated with this solution.

Solutions containing Dextrose may be contraindicated in patients who have a known allergy to corn or corn-derived products.

Allergic reactions or anaphylactoid symptoms may occur during administration, including localized or generalized urticaria (hives) and itching. Other reported symptoms include swelling around the eyes (periorbital), face, or throat (laryngeal edema), as well as coughing, sneezing, and difficulty breathing. These reactions have been reported more frequently in women during pregnancy.

This solution is classified as Pregnancy Category C and may have potential teratogenic effects. It should be administered to pregnant women only if clearly needed. It is not known whether this drug is excreted in human breast milk.

Do not use the solution if it appears cloudy, contains particles, or has passed its expiry date. If chills or rigors occur during infusion for any reason, the administration should be stopped immediately.

Pediatric Use: The safety and effectiveness of this solution in pediatric patients have not been established through adequate and well-controlled clinical trials.
Geriatric Use: Clinical studies have not included enough patients aged 65 years and older to determine whether their response differs from that of younger individuals.

Intravenous fluid preparations

This solution should be stored at a controlled room temperature.